| |
Subscription-based business models are vital for successful direct-to-consumer (DTC) testing. Discover the ins and outs of DTC testing and how to outlast the competition in this free guide. Download Now. 
|
|
Today's Big NewsJan 11, 2023 |
|
March 14-15, 2023 | San Francisco, CA Gain valuable insight from cross-functional team members responsible for search and evaluation, legal/IP, portfolio management, strategic alliances, business development and licensing. Register today to secure our lowest rates! 
|
|
| By Gabrielle Masson,Max Bayer,Annalee Armstrong,James Waldron All you need to know from the second day of the J.P. Morgan Healthcare Conference. |
|
|
|
By Gabrielle Masson,Max Bayer,Annalee Armstrong,James Waldron Join us for a rolling look at the top life sciences news coming out of this year's virtual J.P. Morgan Healthcare Conference. |
By Nick Paul Taylor 4D Molecular Therapeutics has become the latest developer of a Fabry disease gene therapy to run into difficulties. After seeing three cases of a kidney condition in the first six patients, the biotech has decided to stop enrollment and collect more follow-up data before deciding on the next steps. |
Sponsored by Personalis Advanced ctDNA analysis yields biomarkers of cancer dynamics essential in therapeutic monitoring & intervention. Learn how NeXT Personal® detects MRD, monitors variants, & delivers powerful insights. |
|
Thursday, January 19, 2023 | 11:00am ET In this webinar, hear how Novartis uses social data from public forums worldwide to understand the educational and emotional needs of patients with Myelodysplastic Syndromes (MDS), and thereby create more targeted solutions to meet these needs. Register now. 
|
|
By James Waldron Gilmore O’Neill has certainly made an impact in his first six months as CEO of Editas Medicine, culminating in a major pipeline clear out and 20% workforce layoffs this week. But judging by his JPM comments, we shouldn’t expect things to quieten down at Editas anytime soon. |
By Max Bayer BioNTech, the famed maker of the COVID vaccine alongside partner Pfizer, is not giving up on developing an updated shot that protects against infections. The update from CEO Ugur Sahin comes as the company's pipeline has grown to focus on oncology. |
By Annalee Armstrong Sage Therapeutics is trying to pick up pieces of the depression market that have long been left behind, including patients who are not fully served by existing meds and postpartum mothers who have never had an easy, fast option to try. |
By Annalee Armstrong Karuna Therapeutics is 24 months out from a hotly anticipated schizophrenia drug launch and the industry is buzzing with rumors that the biotech will seek a Big Pharma partnership or other deal for commercialization. |
By Nick Paul Taylor BioXcel Therapeutics has reported “promising” top-line data including an “encouraging” response rate in its phase 2 Keytruda combination clinical trial. What is promising and encouraging about the data? That remains under wraps, with the biotech opting against providing even a smidgen of information ahead of the presentation of the full data next month. |
By Helen Floersh Scientists have figured out how disrupted cellular circadian rhythms lead to liver cancer and have shown that by inhibiting key “clock” proteins, they can stop it from growing. |
By Joseph Keenan ClinOne, which develops trial site platforms, and Kayentis have inked a partnership deal in a move to address the growing needs of decentralized clinical trials and hybrid or virtual component trials. |
By Angus Liu After GSK quickly pulled its accelerated approval for Blenrep after a confirmatory trial failure, FDA commissioner Robert Califf has weighed in on the state of the regulatory pathway. |
By Heather Landi SAN FRANCISCO—Ascension Health has charted a $2.5 billion economic recovery plan that executives say has helped the health system to weather ongoing operational challenges and staffing and inflationary pressures. |
By Conor Hale Investments in international manufacturing facilities and component contracts are setting ResMed up to better meet patient needs in 2023 and beyond. |
By Zoey Becker Sanofi has two launches and 27 readouts planned for this year, and CEO Paul Hudson wants to see those numbers again. During a presentation at the J.P. Morgan Healthcare Conference, Hudson said that this is "the new cadence" for the company. |
By Andrea Park SAN FRANCISCO—"There’s nothing more fun than the chaos of success." Dexcom CEO Kevin Sayer discussed the worldwide launch of the newly FDA-cleared G7 glucose monitor with Fierce Medtech at the J.P. Morgan Healthcare Conference on Tuesday. |
Fierce podcasts Don't miss an episode |
| This week on “The Top Line,” we discuss the biotech industry’s rotten tomatoes. Plus, we cover the drug approvals of last year, a congressional report on Biogen's "inappropriate" communications with the FDA and other top headlines from this week. |
|
|---|
|
|
|
Tuesday, January 24, 2023 | 1:00pm ET This session will discuss key 2023 trends for healthcare and life sciences and how organizations should think about their data strategy and interoperability as they navigate the winds of change. Register now. 
|
|
Whitepaper This paper explores how Medical Affairs is adapting medical communications to meet the demands of a new environment (part 5 in a series). Sponsored by: Blue Matter, strategic consultants in the life sciences |
On-Demand Webinar See how high-throughput DNA synthesis combined with antibody engineering expertise provides end-to-end antibody discovery solutions. Sponsored by: Twist Bioscience |
Executive Summary Readers will learn manufacturing by Design Builds on Quality by Design, De-risking the Tech Transfer Process, and more. Sponsored by: Catalent |
Whitepaper How can Lipid-Based Drug Delivery System help bring poorly soluble drugs to market? Sponsored by: Catalent |
Whitepaper Download this paper to learn considerations on how to move a biologic through clinical trials faster, advantages of Parallel Processing, and more. Sponsored by: Catalent |
Whitepaper What are key considerations for intranasal delivery in the treatment of acute and chronic conditions? Sponsored By: Catalent |
Whitepaper Learn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care. Sponsored by: Catalent Biologics |
Whitepaper Learn how Catalent’s extensive network across APAC can meet a wide range of clinical supply needs for sponsors conducting trials within the region. Sponsored by: Catalent |
Whitepaper Explore Catalent’s newest clinical supply facility in Japan, including the comprehensive services & solutions it offers to help support trials both in-country & around the world. Sponsored by: Catalent |
Case Study Learn more on an approach for process characterization for the production of a monoclonal antibody, which will improve the efficiency and effectiveness of the process by targeting the right design and number of experiments. Sponsored by: Catalent |
| |
|
